Trial Profile
Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin. A Ringerike Heart Failure Cohort Phase IV Study of Angiotensin Receptor Neprilysin Inhibiton
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Chronic heart failure
- Focus Pharmacodynamics
- 19 Jun 2018 New trial record